Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
MWN-AI** Summary
Enveric Biosciences (NASDAQ: ENVB) has reported promising data regarding its lead candidate, EB-003, from proprietary bioluminescence resonance energy transfer (BRET) assays. These assays reveal that EB-003 activates both Gq and ?-arrestin signaling pathways downstream of the 5-HT2A receptor, which are linked to antidepressant and anxiolytic effects as supported by multiple peer-reviewed studies. The findings indicate that selective activation of these pathways can result in therapeutic benefits, without the hallucinogenic side effects associated with conventional psychedelics.
Importantly, the newly released results demonstrate that EB-003 exhibits a preference for ?-arrestin signaling over Gq, suggesting its unique therapeutic profile. This bias is significant as it could potentially maximize antidepressant and anxiolytic benefits while minimizing undesirable hallucinations. Enveric is actively exploring the mechanistic implications of this bias.
Furthermore, a recent independent study published in Nature enhances the understanding of the 5-HT2A receptor’s signaling dynamics, identifying that hallucinogenic effects predominantly arise from Gi signaling, thereby demarcating it from the pathways providing therapeutic benefits. This adds weight to Enveric’s goal of developing a non-hallucinogenic neuroplastogenic treatment that could facilitate at-home administration and mitigate the complexities often tied to psychedelic compounds.
The company continues to advance EB-003 through IND-enabling studies and plans to conduct further BRET testing on the Gi pathway to characterize its broader signaling mechanisms. CEO Joseph Tucker emphasizes the importance of these findings in consolidating confidence in Enveric's innovative approach to addressing psychiatric and neurological disorders. As the company progresses, it aims to address unmet needs in mental healthcare while establishing a strong safety profile for its therapies.
MWN-AI** Analysis
Enveric Biosciences (NASDAQ: ENVB) has recently announced promising data regarding its lead candidate, EB-003, which shows dual receptor activation linked to essential therapeutic effects for psychiatric disorders. The proprietary BRET assays reveal significant engagement of both Gq and ?-arrestin signaling pathways through the 5-HT2A receptor. This finding is crucial as it aligns with peer-reviewed studies indicating that manipulation of these pathways can yield antidepressant and anxiolytic benefits without eliciting hallucinogenic effects.
The dual signaling mechanism could position EB-003 as a breakthrough treatment within the growing mental health sector, particularly given the increasing demand for alternatives to traditional psychedelics, which may carry risks of hallucinations. The differentiation of therapeutic benefits from undesirable side effects is an attractive proposition for regulators and the market alike.
However, investors should remain cautious. While the data is promising, Enveric is still in IND-enabling studies, and the progression to clinical trials presents inherent risks. The company's success depends not only on the therapeutic efficacy and safety of EB-003 but also on its ability to secure funding, navigate regulatory hurdles, and potentially fend off competitive pressures in the fast-evolving biotech landscape.
As the market responds to Enveric’s innovative approach, the stock may experience volatility. Therefore, potential investors should closely watch the company’s developments, especially updates on ongoing BRET assays and any forthcoming clinical trial results. It could be prudent to consider a diversified strategy, balancing investment in Enveric with exposure to established players in psychiatry-focused biopharma to mitigate risk.
In summary, while the signaling data supports Enveric's long-term value proposition, careful monitoring of milestones and market conditions will be key in assessing investment opportunities in this dynamic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Proprietary assays demonstrate dual Gq and ?-arrestin signaling at 5-HT? A , pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects
A recent independent Nature study reports that distinct signaling pathways support mechanistic separation of therapeutic benefit from hallucinations
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and ?-arrestin–mediated signaling downstream of the 5-HT? A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT? A receptor, by either Gq-biased or ?-arrestin–biased agonists, can independently produce antidepressant- and anxiolytic-like effects in preclinical models, suggesting that therapeutic benefit can arise from activation of either pathway.
The new data was generated using proprietary bioluminescence resonance energy transfer (BRET) assays. Enveric developed and validated in-house BRET assays to characterize EB-003’s intracellular signaling profile because commercial assays capable of reliably measuring pathway-specific 5-HT? A signaling were not available. The data demonstrate biologically relevant engagement of both Gq and ?-arrestin pathways.
Enveric’s new data also indicate that EB-003 exhibits a modest preference toward ?-arrestin over Gq signaling relative to serotonin, the native ligand of the receptor. Ongoing research is exploring the mechanistic significance of this apparent bias. Importantly, both pathways appear to be engaged at levels consistent with biological relevance.
Independent Academic Findings Support Pathway Separation
A recently published study in Nature employing BRET assays and complementary techniques provides additional mechanistic clarity regarding signaling downstream of 5-HT? A . 1 The study reports that Gi signaling downstream of 5-HT? A was required for hallucinogenic effects in the experimental models evaluated, while Gq signaling mediated antidepressant- and anxiolytic-like benefits in preclinical systems. These findings indicate that therapeutic benefit and hallucinations may arise from distinct intracellular pathways.
“Growing mechanistic clarity around 5-HT? A signaling strengthens confidence in the scientific foundation of our platform,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “Our proprietary BRET assay data show that EB-003 engages signaling pathways that prior peer-reviewed studies have linked to antidepressant- and anxiolytic-like effects in preclinical models.”
Dr. Tucker continued: “Independent academic research further suggests that hallucinogenic effects may arise from a distinct Gi-mediated mechanism. Those findings are consistent with our strategy of designing non-hallucinogenic neuroplastogens intended to deliver therapeutic benefit without the safety, monitoring, and scalability constraints associated with psychedelic compounds. Enveric is planning additional BRET testing of EB-003, including of the Gi pathway, to further characterize its unique signaling mechanisms.”
EB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration. The Company continues to advance EB-003 through IND-enabling studies.
____________________ |
| 1 Xu, Z., Wang, H., Yu, J. et al. Psychedelics elicit their effects by 5-HT 2A receptor-mediated G i signalling. Nature (2026). https://doi.org/10.1038/s41586-025-10061-7 . |
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT? A and 5-HT? B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
For more information, please visit www.enveric.com .
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: develop EB-003 as a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms; conduct additional BRET testing of EB-003, including of the Gi pathway; finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219613461/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
FAQ**
How does the dual Gq and ?-arrestin signaling mechanism in Enveric Biosciences Inc Com ENVB's lead candidate, EB-003, differentiate it from traditional antidepressants in terms of therapeutic benefits?
What are the implications of the findings from the independent Nature study regarding the separation of therapeutic benefits and hallucinations in treatment strategies for Enveric Biosciences Inc Com ENVB's EB-003?
Can you elaborate on the significance of the proprietary BRET assays developed by Enveric Biosciences Inc Com ENVB in characterizing the signaling pathways of EB-003 compared to existing commercial assays?
How does Enveric Biosciences Inc Com ENVB plan to address potential regulatory hurdles in developing EB-003 as a non-hallucinogenic therapeutic while also ensuring efficacy in preclinical and clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Enveric Biosciences Inc Com (NASDAQ: ENVB).
NASDAQ: ENVB
ENVB Trading
-2.13% G/L:
$1.9378 Last:
26,685 Volume:
$2 Open:
